β受体阻滞剂局部外用治疗婴幼儿血管瘤的meta分析  

Meta-analysis onthe treatment of infant hemangioma with topical β-receptor blocker

作　　者：许露 刘海金[3] 陶超[3] 彭威[2] 黄海金[3] 阎金龙[3] 徐仙贇[2] 何晓东[4] 刘潜 

机构地区：[1]广东省妇幼保健医院新生儿外科,广州511400 [2]赣南医学院 [3]赣南医学院第一附属医院小儿外科,赣州341000 [4]重庆金童佳儿童医院外科,重庆400000

出　　处：《中国小儿血液与肿瘤杂志》2016年第2期60-65,共6页Journal of China Pediatric Blood and Cancer

基　　金："江西省赣鄱英才"555工程"领军人才项目;人力资源与社会保障部2011年度留学人员科技启动项目;江西省自然科学基金项目(编号:2010GZY0016);赣南医学院校级课题(编号:YB201322)"资助

摘　　要：目的探讨β受体阻滞剂局部外用对婴幼儿血管瘤的疗效及安全性的研究现状,为临床提供循证医学依据及参考。方法在中英文数据库中检索截至2014年6月的所有关于β受体阻滞剂局部外用治疗婴幼儿血管瘤的文献进行Meta分析。结果利用上述检索策略共检出76篇相关文献,最终纳入文献8篇。(1)β受体阻滞剂局部外用治疗组效果高于安慰剂生臣/观察组,差异有显著性(P<0.00001)。(2)β受体阻滞剂局部外用组疗效和口服普萘洛尔组疗效差异无显著性(P=0.41)。(3)β受体阻滞剂局部外用组全身不良反应少于口服普萘洛尔组,差异有显著性(P=0.002)。结论β受体阻滞剂局部外用疗效和口服普萘洛尔治疗婴幼儿血管瘤无显著差异,全身不艮反应相对更少。Objective This study is aims to provide evidence for evidence-based medicine and reference in clinical through the recta-analysis of the effectiveness and safety of topical β- receptor blocker infant hemangioma therapy. Methods This recta-analysis included literatures were retrieved from all database of China and England by January 2014. Results There are 76 literatures and eight literature were included in this recta-analysis. ① The curative effect of topical β- receptor blocker group was better than placebo/observation group （ P 〈 0. 00001 ） ; ② The effect between topical β- receptor blocker and oral propranolol has no statistically significance difference （ P = 0. 41 ） ;③ The systematic side effect of topical β- receptor blocker are less than oral propranolol （ P = 0. 002 ）. Conclusions There are no difference between topical 13- receptor blocker and oral propranolol to treat infant hemangioma, and the systematic side effect of topicalβ- receptor blocker are less than oral propranolol.

关 键 词：婴幼儿血管瘤 Β受体阻滞剂 噻吗洛尔 普萘洛尔 META分析 

分 类 号：R732.2[医药卫生—肿瘤]